Biotech’s biggest in­vestor is prep­ping a whop­ping $4.75B wa­ger on the fu­ture of the in­dus­try

Don’t ex­pect a lit­tle thing like a mar­ket melt­down in the biotech sec­tor to slow the Or­biMed Ad­vi­sors jug­ger­naut in 2022.

The sec­tor’s largest sin­gle in­vestor just sig­naled Wall Street that it plans to raise $1.9 bil­lion for its next flag­ship fund, a year af­ter its last go-round with $1.5 bil­lion — which it­self set a record dur­ing the big bio­phar­ma pan­dem­ic boom. And that’s not all. Or­biMed Asia’s group post­ed a Form D on a $1.1 bil­lion raise for its ef­forts. Its roy­al­ty and patent arm, mean­while, is out beat­ing the bush­es for $1.75 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.